Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. - Wikidata - awgldk - TriplyDB

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

http://www.wikidata.org/entity/Q36010103

about

The Continuing Value of Ultrastructural Observation in Central Nervous System Neoplasms in Children To BRAF or not to BRAF: is that even a question anymore?Modern brain tumor imaging Pathological and molecular advances in pediatric low-grade astrocytoma Pilocytic astrocytoma: a disease with evolving molecular heterogeneity BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.Pediatric low-grade gliomas: how modern biology reshapes the clinical field.Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade Gliomas.The BRAF kinase domain promotes the development of gliomas in vivo.How molecular testing can help (and hurt) in the workup of gliomas.Model-Based Evaluation of Spontaneous Tumor Regression in Pilocytic Astrocytoma BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the Cerebellum Molecular markers in pediatric neuro-oncology.BRAF Mutation is Associated with an Improved Survival in Glioma-a Systematic Review and Meta-analysis.Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma Biomarker-based prognostic stratification of young adult glioblastoma The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target Management of low-grade gliomas in childhood Molecular markers of glioma: an update on recent progress and perspectives.Targeted therapy in pediatric low-grade glioma.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Advances in the management of low-grade gliomas.Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature.The evolving molecular genetics of low-grade glioma.Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.Low Grade Gliomas in Children.Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.The Effect of Molecular Diagnostics on the Treatment of Glioma.Further understanding of the pathology of glioma: implications for the clinic.An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.Molecular markers in glioma.A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment.Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.Clinical, Imaging, Histopathological and Molecular Characterization of Anaplastic Ganglioglioma.Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.

P2860

Q26784000-3B06F39B-93BB-408A-AD35-5C575BD23094 Q26829788-05BCC019-A1FA-48BD-BDA4-90E97B716459 Q27002344-5C757BDD-25CE-4913-8C19-44B189A3EFB2 Q27026123-D37C5481-430D-4C88-A0C8-E9160A5553CB Q28286218-F74241B9-A6C8-433C-A9DE-6240537B3F76 Q31002780-06FE3EF3-8A31-4132-BBA6-600DD945A049 Q33847771-FB23EBB8-5887-469E-BEBF-70C11797A249 Q34810518-66A74282-C6DD-4013-814F-41FFC8C600E9 Q35184491-3358BE89-24B2-4290-BDAE-54BD0FB9348E Q35770275-7A3018CA-BC07-4103-86DC-38C867F95986 Q35866716-BA97D8E4-A787-4657-ADB6-CEDE698826D0 Q36009738-4C416273-0820-40B1-8ED9-2E8FCA1E0BEC Q36344704-915CE75D-0168-4BB6-8320-8348AA3095B2 Q36378426-88513ECE-26A3-4F5E-B0BC-E20624DA84BB Q36618268-450736C9-FDD1-4CCB-B78E-AB34D1EC93F2 Q36745457-E684AE19-561E-4812-912D-F0E9997FBE7B Q36782664-17CB9F67-7A18-4C2F-802F-E9D6C7B1A038 Q36833480-6ED5DF9F-4BCF-4107-87FC-0ECD75506CC5 Q37221110-8EBC85C3-5D42-4E59-BE4F-BB7EAFB5D3D9 Q37312742-DCF5F2B4-6C48-444C-8CBF-E756A4A98130 Q37629508-D7D9C6A1-D604-4882-965F-64D325BD29CB Q38050966-9BEC182B-001D-4144-B5C0-A5A8FA051619 Q38194055-FA3E56BE-A8E3-403B-9D8B-58852FA4D0CB Q38203283-89DEABC0-D480-4125-98F1-C552D2952C29 Q38219898-9B35AC15-75E7-461E-B6B1-813D95DC844A Q38239310-5AFD886D-B9C6-49EA-AC9D-05A44DF14D59 Q38349169-8FBBF493-8BEB-4B07-AF34-10C3E1E471B9 Q38382607-9AC7D78F-B5DA-4584-B3FE-B429AA833A6E Q38569310-6922CDBC-ECF3-4642-9337-1A204A3A8A97 Q38670250-41F3F58B-5132-452C-88EE-B61C0DA1749E Q38743781-96481D5A-D57C-4758-8416-50398FAA7B84 Q38844945-6F326C94-266D-4DE5-B05B-D95F9975C604 Q38962177-6998DA5B-0A5F-4C9C-83AE-11701CF7D869 Q39148751-D4E7A399-B521-42B6-BF95-1FD17A6049EA Q39200135-4703EDBF-2F11-4CF6-9951-29A499DB2901 Q39203692-E024E064-0906-4748-92A6-7552E2E4E741 Q39475786-4EFD1290-32AB-4DA4-A5FF-F197C527B2AC Q41346638-283F67F9-368E-40BF-BC94-A7894C4FBA2D Q41491998-6201C54F-02E3-4B06-93DD-BBE937362D08 Q41493335-B0369E36-D233-42FD-9B41-599F51406353

P2860

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

http://www.wikidata.org/entity/Q36010103

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

@ast

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

@en

type

label

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

@ast

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

@en

prefLabel

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

@ast

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

@en

P1433

Q36010103-34686A20-CB5C-40CA-A17B-109DDF5DF0E9

P1476

Q36010103-5E08D706-5483-4823-B541-24E81C3E98B1

P2093

Q36010103-48095604-A6AC-4771-9060-5CB63DCF829A

Q36010103-5C14B267-7C7E-4258-B87F-8828FD88871F

Q36010103-9F49A95B-5F3C-4427-8A02-13D92C49BFC2

Q36010103-C18F4C79-AE27-4DA2-833E-958C1FFB34E7

Q36010103-FFD0E795-59D9-45AF-8B8C-9921832D37D5

P2860

Q36010103-04201D49-5022-4372-915F-76B35B00801A

Q36010103-1210E0FC-EF45-47B0-A20E-67533C5801A4

Q36010103-1228BB0D-DEDF-4E36-B37C-1EE8AAFE116B

Q36010103-1AF53228-CC90-42A9-AA14-140D9E6D14F0

Q36010103-1E2FE64E-769D-49D2-A86D-83CAE00F443F

Q36010103-215BD1CB-270E-465F-B27B-7D7BF14D65F2

Q36010103-36B71895-2F22-4F41-AE4D-6A2B488C9D64

Q36010103-388C9407-21E8-45BB-A61C-175070E22A87

Q36010103-422C9433-8EFD-4DE2-8A65-2F5863CF2D10

Q36010103-427C8BD9-10D6-419F-B1C2-BE17D874497D

P304

Q36010103-DD0C9F57-0FAE-47AC-983D-F3170C5C3E44

P31

Q36010103-D3AA0FB0-554D-462F-B73D-B1B7AA167CA1

P356

Q36010103-56853F79-1F14-40A5-B107-C245A028B789

P433

Q36010103-37BC3F05-D75D-455A-85C2-004405C7A0AF

P478

Q36010103-80065695-2FAB-493B-B5E8-963D396B8781

P577

Q36010103-E0B20D3B-A3DB-49EF-A8BD-3F1648ACCAFA

P5875

Q36010103-1E2637D5-3932-44B2-B975-5B27179338EF

P698

Q36010103-1BDB2F0E-08DF-43C1-BBBA-E8D70ECD60CA

P932

Q36010103-C0C5254A-D8B3-46CC-AFA1-1A81064B85C6

P356

P1433

P1476

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

@en

P2093

Craig Horbinski

http://www.w3.org/2001/XMLSchema#string

Ian F Pollack

http://www.w3.org/2001/XMLSchema#string

Jill M Hagenkord

http://www.w3.org/2001/XMLSchema#string

Marina N Nikiforova

http://www.w3.org/2001/XMLSchema#string

Ronald L Hamilton

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.

BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.

An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice

Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome.

PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.

P304

777-789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOS077

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223974335

http://www.w3.org/2001/XMLSchema#string

P698

22492957

http://www.w3.org/2001/XMLSchema#string

P932

3367847

http://www.w3.org/2001/XMLSchema#string